Oxford Brookes U. patent anti-Activin Beta-B|CAS|DC Chemicals

Cas No.:
pH value:	Corresponds to reference standard: PASS
Non-reduced CE-SDS:	>95%
SEC-HPLC:	>95%
Isoelectric Point:	Corresponds to reference standard
Osmolality:	Corresponds to reference standard: PASS
Peptide mapping:	Corresponds to reference standard: PASS
N-terminal sequence:	Corresponds to reference standard: PASS

MSDS

Cat. No.	Product name	Field of application
A901	Losatuxizumab	Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFRC271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers.
A900	Serclutamab	Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells.
A899	Demupitamab
A898	Abbott patent anti-EPO Receptor
A897	VasGene patent anti-EphB4
A896	Morphosys patent anti-EphB4
A895	Genentech patent anti-EphB2
A894	Ifabotuzumab
A893	Adecatumumab	Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status.
A892	Oportuzumab